Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Systemic lupus erythematosus
Last updated:
January 18, 2024
Status:
Concluded with an LOI
Manufacturer:
Sobi Canada Inc.
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH) in adult patients who have an inadequate response to, or are intolerant of, a C5 inhibitor
Last updated:
January 17, 2024
Status:
Concluded without agreement
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Breast cancer, Locally advanced, inflammatory, or early stage HER2-positive (either 2 cm in diameter or node positive), for neoadjuvant treatment of patients (in combination with trastuzumab and chemotherapy)
Last updated:
December 21, 2023
Status:
Concluded with an LOI
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated:
December 17, 2023
Status:
Concluded with an LOI
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated:
December 17, 2023
Status:
Concluded with an LOI
Manufacturer:
AVIR Pharma Inc.
Indication:
Ulcerative Colitis
Last updated:
December 17, 2023
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic fibrosis, F508del CFTR mutation, 2 years and older
Last updated:
December 12, 2023
Breyanzi (lisocabtagene maraleucel)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
Last updated:
December 12, 2023
Status:
Negotiations were not pursued
Manufacturer:
Sandoz Canada Inc.
Indication:
Intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL), addition to front-line multi-agent therapy of pediatric, adolescent, and young adult (AYA) patients (aged 1 year to 30 years at diagnosis)
Last updated:
December 4, 2023
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Adjunct to standard of care therapy for chronic kidney disease and type 2 diabetes
Last updated:
November 16, 2023